Medicines Healthcare Products Regulatory Agency
class="gem-c-govspeak govuk-govspeak gem-c-govspeak--direction-ltr govuk-!-margin-bottom-0">
The Medicines and Healthcare products Regulatory Agency (MHRA) published its first Patient Involvement Strategy in October 2021, covering the period to 2025. This defined how we would engage and involve the public and patients in our work.
The MHRA has regulatory responsibilities across the different stages of development of a medicine or device, referred to as the product lifecycle. In early 2023, a One-year-on report was published outlining early changes we were making to engage more meaningfully with public and patients across this regulatory lifecycle. The report covered examples of activities between October 2021 to September 2022.
In mid-2023, two years into implementation of the strategy, we undertook an interim assessment of progress to gauge whether the changes being made were the right ones and to inform a refresh of the strategy from 2026 onwards. This report outlines what we have found.